Breast cancer is the first malignant tumor that threatens women's health in China. On March 8th, International Women's Day, Lilly China announced its new breast cancer drug CDK 4&; The only inhibitor (Abeceli tablets) was officially listed in China, and millions of breast cancer patients in China ushered in new survival expectations.

Professor Shao Zhimin from the Cancer Hospital affiliated to Fudan University believes that the successful listing of Acesulfame K in Chinese mainland will further change the survival outcome of breast cancer patients in China, and it is expected that more patients will live longer and better.

Extended data

In 2020, breast cancer will become the cancer with the most new cases in the world;

Among the subtypes of advanced breast cancer, HR+ and HER2- are the most common, accounting for about 60%. According to the latest statistics of the International Agency for Research on Cancer, in 2020, breast cancer has surpassed lung cancer and become the cancer with the most new cases in the world. In 2020 1 year alone, the number of new cases of breast cancer in China is as high as 410.6 million, and the death toll is about1/0.7 million, accounting for about 17.438+0% of all breast cancer deaths in the world.

Lilly said that clinical trials showed that Agbesi combined with aromatase inhibitor or fulvestrant could improve the disease-free survival of patients with HR+ and HER2- advanced breast cancer compared with endocrine monotherapy.

Interface news-On the day of Women's Day, a drug that can treat early breast cancer went on the market.